A Message From Brownstone Research

Dear Reader,

Do you hold any of these AI stocks?

Wall Street insider Jason Bodner — the man who called Nvidia at $4.50 — says today’s AI stocks are about to hit a wall.

And a completely different group of AI firms… names Wall Street is starting to ignore… are about to take off.

This has nothing to do with SpaceX…

A new chatbot…

Autonomous robots…

Or anything you’re likely hearing about.

It has to do with a brand-new “light-speed” device turning AI as we know it into “Accelerated AI”…

Making it 100 times faster…

And 100 times more energy efficient — right here, on Earth.

Already, some of the biggest tech investors like Elon Musk, Mark Zuckerberg, Cathie Wood, and Bill Gates are moving money into it.

Just to name a few…

They’re all moving money to prepare for what’s coming.

But you won’t hear anything about it in the mainstream news…

In fact, TV pundits spent most of this past year talking about AI worries and its “existential risk” to jobs…

Or arguing whether we’re in an AI bubble and when it would pop…

That’s why most Americans won’t see it coming until it’s too late.

Don’t be one of them…

Because if you’re holding the wrong AI stocks when “Accelerated AI” goes mainstream…

You could spend the next decade just trying to claw back to even…

But if you make the one move Jason reveals in this urgent video message…

The next 12 to 24 months could hand you bigger gains than the entire AI boom of the last three years.

Click here to hear the full story and get ahead of the crowd.

But hurry, because this opportunity won’t stay hidden much longer.

We have so much to look forward to,

Jeff Brown
Founder & CEO, Brownstone Research

P.S. Jason also shares details on 10 popular AI stocks he says you must dump before this shift goes mainstream. Names sitting in millions of 401(k)s, IRAs, and brokerage accounts. Click here to see if yours made the list.

Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid

Reported by Jeffrey Neal Johnson. First Published: 9/15/2026.

Cross-border consolidation in the cannabis industry has moved from executive speculation to aggressive dealmaking. As regulatory hurdles begin to clear across North America and Europe, operators are moving quickly to strengthen their finances and expand globally.

Curaleaf Holdings, Inc. (OTCMKTS: CURLF) bypassed management resistance and took an acquisition proposal directly to Aurora Cannabis Inc. (NASDAQ: ACB) shareholders. By offering a cash-and-stock package valued at about $4 per share, Curaleaf is attempting to build an international commercial footprint spanning 17 countries.

For investors tracking capital flows and federal policy changes, this hostile bid signals that the era of fragmented regional cannabis operators may be coming to a close. The proposed deal also shows how industry leaders are using their financial strengths to gain scale ahead of expected federal reforms.

Curaleaf Takes Its Case to Shareholders

The deal began when Curaleaf went public with its formal tender offer, appealing directly to shareholders after private merger discussions stalled. The proposal offers 0.3463 Curaleaf common shares and 75 cents in cash for each Aurora Cannabis share tendered. Based on Aurora Cannabis's unaffected 30-day volume-weighted average price (VWAP) of $2.76 on Aug. 10, 2026, the bid implies a purchase price of $4 per share, representing a 45% acquisition premium.

Shareholder tensions escalated on Sept. 14, 2026, when Curaleaf filed an application with the Alberta Securities Commission seeking an order to cease trading or halt Aurora Cannabis's active at-the-market (ATM) equity distribution facility. Curaleaf contends that Aurora Cannabis's leadership is using continuous share issuances as a defensive maneuver to dilute voter concentration and entrench management.

In recent years, Aurora Cannabis has raised more than $400 million through equity offerings, selling shares for as little as $2.60 in July 2026. Curaleaf Chairman Boris Jordan scheduled an open shareholder webcast for Sept. 17, 2026, to present the strategic case directly to investors ahead of the Dec. 1, 2026, tender expiration.

Combining High Sales With Low Leverage

Beneath the boardroom fight lies a compelling balance-sheet transaction. Curaleaf operates at substantial scale in the domestic market, recording annual net revenue of about $1.27 billion. In its latest quarterly report, the company delivered $340.1 million in revenue and adjusted earnings per share of 5 cents, outperforming consensus estimates. Continued expansion in state-level retail has left Curaleaf with a debt-to-equity ratio of 1.06 and operating cash flow of 17 cents per share.

In contrast, Aurora Cannabis provides a cash-rich, low-leverage balance sheet. The company has a minimal debt-to-equity ratio of 0.03 and a current ratio of 5.36, along with a book value of $6.27 per share. Despite these balance-sheet strengths, Aurora Cannabis faces operational headwinds, including an annual revenue base of about $247.82 million, a negative net profit margin of 32.26%, and several quarters of top-line contraction.

Acquiring Aurora Cannabis would allow Curaleaf to absorb liquidity at roughly 0.60 times book value. Pro forma estimates indicate that the combined organization would generate more than $1.5 billion in annual revenue and approximately $350 million in adjusted EBITDA. Eliminating duplicate public-listing expenses, centralizing supply-chain logistics, and streamlining corporate overhead could produce at least $40 million in annualized cost efficiencies and operational savings.

German Exports Meet American Reform

The timing of this takeover bid aligns with regulatory tailwinds in both North America and Europe. In the U.S., administrative momentum surrounding the potential reclassification of cannabis under Schedule III of the Controlled Substances Act could eliminate the impact of Internal Revenue Code Section 280E.

This federal tax provision prevents cannabis operators from deducting ordinary business expenses, frequently pushing effective corporate tax burdens above 70%. Removing Section 280E would expand Curaleaf's cash flow and ease the capital required to fund the 75-cent cash component of the tender offer.

At the same time, Aurora Cannabis provides a turnkey medical-export platform that U.S. operators cannot build domestically under existing federal restrictions. The company holds established distribution agreements across mature medical markets, including Germany, the United Kingdom, Poland and Australia.

Following recent German medical cannabis reforms that simplified patient prescription procedures, demand for standardized, pharmaceutical-grade imports has expanded significantly. Merging Curaleaf's domestic retail presence with Aurora Cannabis's international commercial network would provide immediate access to European health care channels.

The Green Spread: Why MSOS Call Volume Points to a Re-Rating

Public-market pricing reflects growing confidence in cross-border consolidation. With Aurora Cannabis shares trading near $3.80, the stock sits at a narrow 5% discount to the implied $4 acquisition price. This tight arbitrage spread suggests that the market anticipates either successful deal completion or a sweetened bid from the acquirer.

Institutional sentiment is also visible across sector exchange-traded funds. AdvisorShares Pure US Cannabis ETF (NYSEARCA: MSOS) saw a sharp surge in derivatives positioning, recording daily volume of 52,583 contracts. Options flows showed an extreme call-side skew, with 46,416 call options trading against just 6,167 put options, resulting in an 88.3% call ratio.

Because Curaleaf accounts for about 21.6% of the underlying fund exposure through direct stock and swap contracts, institutional desks appear to be using the ETF to position for broader valuation re-ratings. Elevated short interest of roughly 9.79 million shares adds fuel to a potential short-covering advance if consolidation gains momentum.

Assessing the Risks and Weighing the Upside

Investors monitoring the cannabis sector should view this hostile bid as a potential catalyst for widespread industry realignment. Aurora Cannabis shareholders must weigh the potential liquidity provided by a 45% premium against management's standalone turnaround timeline before the Dec. 1, 2026, deadline. Immediate investor focal points include the Sept. 17 executive Q&A, the pending Alberta Securities Commission ruling on the ATM facility and upcoming quarterly corporate filings.

While integration challenges and potential regulatory delays in cross-border approvals remain risks, the commercial logic of combining scale, international reach and balance-sheet liquidity is difficult to dismiss. Investors seeking exposure to sector-wide consolidation might consider Curaleaf for its established market presence or monitor Aurora Cannabis to evaluate event-driven arbitrage spreads. Those seeking broader exposure without single-operator regulatory risk may consider diversified funds such as the AdvisorShares Pure US Cannabis ETF on minor price pullbacks as federal policy shifts unfold.